Pilot assessment of clinical and laboratory manifestations dynamics in patients with moderate coronavirus disease-19 (COVID-19) during the first week of hospitalization


DOI: https://dx.doi.org/10.18565/therapy.2021.4.34-40

Izmozherova N.V., Popov A.A., Tsvetkov A.I., Borzunov I.V., Stepanov A.I., Prokopieva E.R., Bakhtin V.M., Vikhareva A.A., Kadnikov L.I.

1) Ural State Medical University of the Ministry of Healthcare of Russia, Yekaterinburg; 2) Central City Clinical Hospital No. 6, Yekaterinburg
Abstract. Purpose: to evaluate clinical symptoms and laboratory parameters dynamics in patients with coronavirus disease-19 during hospitalization first week.
Material and methods. The prospective study included 38 patients (21 women and 17 men) with moderate coronavirus disease-19. Questioning, clinical examination and laboratory parameters estimation were carried out. The European life quality questionnaire and health visual-analog scale (VAS) were used. General blood analysis was evaluated. Patients were examined at the hospitalization moment and after 7 days. Statistical analysis was carried out with Wilcoxon and McNemar’s tests in critical p-value<0.050. Data were presented as median and quartiles.
Results. Patients were hospitalized on average 7 (5÷10) days after the disease onset. During the observation period there was decreasing number of patients’ suffering from cough (from 27 to 21; p=0,041), breath shortness (from 15 to 8; p=0,045), anosmia (from 14 to 2; p=0,001), dysgeusia (from 10 to 2; p=0,027), weakness (from 30 to 17, p=0,002), headache (from 21 to 10; p=0,022), myalgia (from 11 to 3, p=0.013), nausea (from 9 to 3; p=0,041). Health general state improved from 60 (50÷75) to 80 (55÷87) points (p <0,001), discomfort feeling decreased from 2 (1÷2) to 1 (1÷2) points (p=0,025). During the week, hemoglobin concentration decreased from 137,5 (128,0÷145,0) g/l to 125,5 (119,0÷136,0) g/l (p <0,001) and the platelet count increased from 217,5 (179,0÷279,0) 109/ l to 295,0 (235,0÷367,0) 109/l (p=0,027).
Conclusion. During the first week of hospitalization, weakness, headache, myalgia, breath shortness, cough, anosmia, dysgeusia, nausea regress, the hemoglobin level decreases, the platelet count increases moderately.
Keywords: COVID-19 dynamics, COVID-19 symptoms, coronavirus disease-19, laboratory parameters, SARS-CoV-2, COVID-19
Read entire article

Literature


  1. Fu L., Wang B., Yuan T. et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020; 80(6): 656–65. doi: 10.1016/j.jinf.2020.03.041.

  2. Xie Y., Wang Z., Liao H. et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020; 20(1): 640. doi: 10.1186/s12879-020-05371-2.

  3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 7 (03.06.2020). Доступ: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf (дата обращения – 09.01.2021). [Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Version 7 (06/03/2020). Available at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf (date of access – 09.01.2021) (In Russ.)].

  4. Costa K.V.T.D., Carnauba A.T.L., Rocha K.W. et al. Olfactory and taste disorders in COVID-19: a systematic review. Braz J Otorhinolaryngol. 2020; 86(6): 781–92. doi: 10.1016/j.bjorl.2020.05.008.

  5. Vaira L.A., Salzano G., Fois A.G. et al. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy. Rhinol. 2020; 10(9): 1103–04. doi: 10.1002/alr.22593.

  6. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281–86. doi: 10.1007/s12098-020-03263-6.

  7. D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea during COVID-19 infection: Pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020; 18(8): 1663–72. doi: 10.1016/j.cgh.2020.04.001.

  8. Grassia R., Testa S., Pan A., Conti C.B. SARS-CoV-2 and gastrointestinal tract: The dark side of the pandemic. Dig Liver Dis. 2020; 52(7): 700–01. doi: 10.1016/j.dld.2020.04.028.

  9. Zhao Q., Fang X., Pang Z. et al. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020; 34(11): 2505–10. doi: 10.1111/jdv.16778.

  10. Matar S., Oules B., Sohier P. et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2020; 34(11): e686–e689. doi: 10.1111/jdv.16775.

  11. Wenzhong L., Hualan L. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. Available at: https://chemrxiv.org/articles/preprint/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173/9 (date of access – 09.01.2021). doi: 10.26434/chemrxiv.11938173.v9.

  12. Cavezzi A., Troiani E., Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin. Pract. 2020; 10(2): 1271. doi: 10.4081/cp.2020.1271

  13. Soraya G.V., Ulhaq Z.S. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. Med Clin (Barc). 2020; 155(4): 143–51. doi: 10.1016/j.medcli.2020.05.017.

  14. Violi F., Pastori D., Cangemi R. et al. Hypercoagulation and antithrombotic treatment in coronavirus 2019: A new challenge. Thromb Haemost. 2020; 120(6): 949–56. doi: 10.1055/s-0040-1710317.


About the Autors

Nadezhda V. Izmozherova, MD, head of the Department of pharmacology and clinical pharmacology, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: nadezhda_izm@mail.ru. ORCID: 0000-0001-7826-9657
Artem A. Popov, MD, head of the Department of hospital therapy and urgent medical care service, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: art_popov@mail.ru. ORCID: 000-0001-6216-2468
Andrey I. Tsvetkov, PhD, head of the Department of public welfare and public health, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: cp-gendir@mail.ru. ORCID: 0000-0002-8751-672.
Igor V. Borzunov, MD, professor of the Department of urology, nephrology and transplantology, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: ivborzunov@e1.ru. ORCID: 0000-0002-9827-8451
Alexander I. Stepanov, Chief physician of Central City Clinical Hospital No. 6 of Yekaterinburg. Address: 620149, Yekaterinburg, 34 S. Deryabinoy Str. Tel.: +7 (343) 389-26-09. E-mail: mbucgkb6@mail.ru
Elmira R. Prokopieva, PhD, Deputy Chief physician of Central City Clinical Hospital No. 6 of Yekaterinburg. Address: 620149, Yekaterinburg, 34 S. Deryabinoy Str. Tel.: +7 (343) 389-26-05. E-mail: mbucgkb6@mail.ru
Viktor M. Bakhtin, postgraduate student of the Department of pharmacology and clinical pharmacology, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: bakhtin.v95@mail.ru. ORCID: 0000-0001-7907-2629
Anna A. Vikhareva, postgraduate student of the Department of pharmacology and clinical pharmacology, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: anna1993vi@gmail.com. ORCID: 0000-0002-5951-2110
Leonid I. Kadnikov, resident of the Department of pharmacology and clinical pharmacology, Ural State Medical University of the Ministry of Healthcare of Russia. Address: 620028, Yekaterinburg, 3 Repina Str. Tel.: +7 (343) 214-86-52. E-mail: kadn-leonid@mail.ru. ORCID: 0000-0002-2623-2657


Similar Articles

Back to Content

Бионика Медиа